19 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
23103095	125	Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.	Abbott Laboratories
20471253	32	Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines.	Boehringer Ingelheim Pharmaceuticals
20000469	179	Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.	Boehringer Ingelheim Pharmaceuticals
16408091	2	Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro.	Harvard Medical School
20462760	70	Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.	Boehringer Ingelheim Pharmaceuticals
19716293	22	Structure-activity relationship of isoform selective inhibitors of Rac1/1b GTPase nucleotide binding.	Exonhit Therapeutics
23952265	84	Testing the substrate-envelope hypothesis with designed pairs of compounds.	Massachusetts Institute of Technology
23899657	3	Binding of (5S)-penicilloic acid to penicillin binding protein 3.	University of Oxford
24171552	52	Expanding the Scope of Human DNA Polymerase ¿ and ß Inhibitors.	University of Konstanz
24070067	20	Fluorescence Linked Enzyme Chemoproteomic Strategy for Discovery of a Potent and Selective DAPK1 and ZIPK Inhibitor.	Duke University Medical Center
24004176	16	Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors.	Georgia Institute of Technology